Evidence map›Paper›PMID 39297909›Full record

Observational studyInternational journal of clinical oncology2024

Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer.

Hiroki Inada, Hideaki Miyamoto, Satoru Shinriki, Hisanobu Oda, Satoshi Narahara, Motohiro Yoshinari, Katsuya Nagaoka, Daiki Yoshii, Kotaro Fukubayashi, Hiromitsu Hayashi and 3 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Clinical Medicine Insights. Oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hiroki InadaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Hideaki MiyamotoDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Satoru ShinrikiCancer Genome Center, Kumamoto University Hospital, Kumamoto, Japan.
Hisanobu OdaDivision of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
Satoshi NaraharaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Motohiro YoshinariDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Katsuya NagaokaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Daiki YoshiiDepartment of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.
Kotaro FukubayashiDepartment of Gastroenterology, Kumamoto Kenhoku Hospital, Kumamoto, Japan.
Hiromitsu HayashiDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kisato NosakaCancer Genome Center, Kumamoto University Hospital, Kumamoto, Japan.
Yasuhito TanakaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan. ytanaka@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0002-2473-6966

Funding

Japan Agency for Medical Research and Development JP24fk0210103JSPS Grants-in-Aid for Scientific Research 22K16023Kumamoto University Hospital Young Researcher Activation Project R5-2
6 · The paper itself

Abstract

backgroundBiliary tract cancer (BTC) comprises a heterogeneous group of malignancies with poor prognosis because of the limited treatment options. With the recent advances of next generation sequencing technologies, comprehensive genomic profiling (CGP) tests have been widely introduced into daily clinical practice. PATIENTS AND

methodsWe performed a retrospective, multicenter, observation cohort study. The genomic and clinical data of 85 BTC patients, who underwent CGP testing from August 2021 to September 2023, were analyzed.

resultsThere were 62 (73%) cases in which treatment recommendations were raised during expert meetings, including 34 intrahepatic cholangiocarcinoma (ICC), 20 extrahepatic cholangiocarcinoma (ECC) and 8 gall bladder carcinoma (GBC). The drug accessibility rate of the BTC patients was 15.3% (13 cases): ten ICCs, two ECCs, and one GBC. Five ICC patients (three male and two female) with the FGFR2 fusion gene were treated with pemigatinib. Those patients who received a genomically matched therapy had significantly longer median overall survival than those patients who not received. (n = 13; not reached [95% CI not reached-not reached] vs n = 72; 8.6 months [95% CI 6.6-10.0]; hazard ratio 0.24 [95% CI 0.12-0.49], p = 0.013). The median observation period of pemigatinib treatment was 15.4 months (range 10.1-27.4). The responses were classified as PR in three patients, SD in one patient and PD in one patient. The median progression free survival is 9.0 months. No patient had grade 3/4 AEs requiring discontinuation of the treatment.

conclusionThe drug accessibility rate of ICC is high and pemigatinib is effective and well-tolerated in ICC patients harboring FGFR2 gene fusions.

Indexed as

Biliary Tract NeoplasmsAdultAgedAged, 80 and overCholangiocarcinomaFemaleGenomicsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedReceptor, Fibroblast Growth Factor, Type 2Retrospective StudiesFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2Biliary tract cancerComprehensive genomic profilingFGFR2 fusionGenomically matched therapyPemigatinib

Identifiers

PMID39297909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.